Rami Shoufani

Dr. Rami Shoufani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Life
Verified
Journal Article
Open access
PDF file
RSRami Shoufani
Rami Shoufani
ABAriel Berl
Ariel Berl
OSOfir Shir-Az
Ofir Shir-Az
DKDeborah Kidron
Deborah Kidron
DMDin Mann
Din Mann
ASAvshalom Shalom
Avshalom Shalom
Dermatofibrosarcoma protuberans (DFSP) is a rare, soft-tissue sarcoma characterized by dermal, finger-like projections and high local recurrence rates. Complete surgical excision is the primary treatment goal and Mohs micrographic surgery (MMS) is the accepted approach for achieving disease-free margins. Despite the effectiveness of MMS, it has limitations when treating DFSP, with documented local recurrences. This paper presents our experience and treatment modality for DFSP, using MMS with an additional “safety margin”. This technique seeks to ensure free surgical margins and potentially lower recurrence rates. This is a retrospective analysis of patients treated for DFSP over a 10-year period. All patients underwent MMS, followed by an additional, circumferential excision of 2–5 mm. Twenty-two patients were treated surgically for DFSP from 2014 to 2023. The median age at presentation was 42.5 years. Four patients (18%) had positive disease margins on the additional safety marginal excision, two had negative MMS slides, and the other two were positive for DFSP. The mean follow-up time was 27 months, and no local recurrences were observed during that time. The surgical method presented here includes an additional excision of the surrounding margins following MMS for DFSP. This technique provides a tool to overcome the limitations of MMS in treating this tumor, aiming to reduce local recurrence.

28 October 2026 in The American Journal of Cosmetic Surgery
Verified
Journal Article
Closed access
RSRami Shoufani
Rami Shoufani
ABAriel Berl
Ariel Berl
BBBiader Samih Bilal
Biader Samih Bilal
ANAriel Neiman
Ariel Neiman
ASAvshalom Shalom
Avshalom Shalom
Hyaluronic acid (HA) is a widely used dermal filler used for facial rejuvenation and contouring. Its use has expanded to off-label applications like breast augmentation, despite limited safety data and lack of regulatory approval for this indication. We present a single-patient case report of a severe complication following bilateral HA injection for breast augmentation. Clinical data were collected from the patient’s hospital course, laboratory results, imaging studies, intraoperative findings, microbiological cultures, and outpatient follow-up. A female patient presented several days after bilateral breast augmentation with HA injections, with bilateral breast swelling, erythema, pain, and signs of evolving sepsis. Imaging demonstrated extensive multiloculated fluid collections consistent with abscess formation. Intraoperative exploration revealed diffuse HA deposits mixed with purulent material and scattered necrotic breast tissue bilaterally. Although Sepsis-3 septic shock criteria were not fully met on arrival, the patient deteriorated perioperatively and subsequently required intensive care unit admission and vasopressor support. This case demonstrates the potential severity of complications following large-volume HA injection into the breast. The diffuse distribution of filler within breast tissue complicated complete removal and contributed to prolonged surgical and wound management. In addition to infection risk, HA breast injection may create diagnostic challenges in breast imaging and may result in long-term aesthetic deformity. Hyaluronic acid injection for breast augmentation may lead to severe, life-threatening complications. Given these risks, HA filler procedures should be strictly regulated and performed only within approved indications.